

Alessia Alunno

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7710317/alessia-alunno-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

3,142
citations

30
h-index

53
g-index

148
ext. papers

4,172
ext. citations

4.5
avg, IF

5.44
L-index

#	Paper	IF	Citations
129	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745	2.4	628
128	Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. <i>Mediators of Inflammation</i> , 2015 , 2015, 751793	4.3	178
127	Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 823085		108
126	Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. <i>Journal of Autoimmunity</i> , 2014 , 51, 75-80	15.5	97
125	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's	13.6	84
124	IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 286-92	2.4	73
123	One year in review 2017: pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 368-378	2.2	72
122	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019 , 18, 93-106	13.6	63
121	Diagnosis and classification of autoimmune hypophysitis. <i>Autoimmunity Reviews</i> , 2014 , 13, 412-6	13.6	62
120	One year in review 2019: pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 347-357	2.2	61
119	One year in review 2018: pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 175-184	2.2	58
118	Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. <i>Autoimmunity Reviews</i> , 2015 , 14, 1019-22	13.6	56
117	Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets. <i>BMC Rheumatology</i> , 2017 , 1, 3	2.9	55
116	Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. <i>Cells</i> , 2019 , 8,	7.9	54
115	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 314-24	5.3	54
114	CD4(-)CD8(-) T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement. <i>Journal of Autoimmunity</i> , 2014 , 51, 38-43	15.5	53
113	One year in review: the pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 551-8	2.2	49

112	GITR+ regulatory T cells in the treatment of autoimmune diseases. <i>Autoimmunity Reviews</i> , 2015 , 14, 117-266	3.6	47
111	Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome. <i>Rheumatology</i> , 2013 , 52, 1387-96	3.9	46
110	Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. <i>RMD Open</i> , 2020 , 6,	5.9	45
109	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. <i>Mediators of Inflammation</i> , 2015 , 2015, 243723	4.3	44
108	One year in review 2017: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 551-561	2.2	42
107	Telocytes in minor salivary glands of primary Sjögren's syndrome: association with the extent of inflammation and ectopic lymphoid neogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 1689-96	5.6	41
106	Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. <i>Autoimmunity Reviews</i> , 2012 , 11, 815-20	13.6	41
105	Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome. <i>Frontiers in Medicine</i> , 2018 , 5, 102	4.9	38
104	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017 , 16, 253-257	13.6	37
103	In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjögren's syndrome. <i>Rheumatology</i> , 2015 , 54, 163-8	3.9	37
102	Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients. <i>Arthritis Research and Therapy</i> , 2014 , 16, 444	5.7	35
101	Polar Constituents and Biological Activity of the Berry-Like Fruits from <i>Hypericum androsaemum</i> L. <i>Frontiers in Plant Science</i> , 2016 , 7, 232	6.2	34
100	Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. <i>Nature Reviews Cardiology</i> , 2018 , 15, 33-44	14.8	33
99	Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren's syndrome: new markers of chronic endothelial damage?. <i>Rheumatology</i> , 2015 , 54, 536-44	3.9	29
98	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting?. <i>Autoimmunity Reviews</i> , 2014 , 13, 1167-73	13.6	29
97	Antioxidant and Immune System Regulatory Properties of Extracts. <i>Oxidative Medicine and Cellular Longevity</i> , 2017 , 2017, 7468064	6.7	28
96	Cardiovascular disease in systemic sclerosis. <i>Annals of Translational Medicine</i> , 2015 , 3, 8	3.2	26
95	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	26

94	One year in review 2016: pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 793-801	2.2	25
93	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1727-37	5.4	24
92	Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. <i>Scientific Reports</i> , 2021 , 11, 4863	4.9	23
91	One year in review 2020: pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 387-397	2.2	23
90	Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. <i>Rheumatology</i> , 2018 , 57, 850-855	3.9	22
89	Post-Translational Modifications of Proteins: Novel Insights in the Autoimmune Response in Rheumatoid Arthritis. <i>Cells</i> , 2019 , 8,	7.9	21
88	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	21
87	COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 748-753	2.2	21
86	Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz112	1	20
85	Interferon gamma-inducible protein 16 in primary Sjögren's syndrome: a novel player in disease pathogenesis?. <i>Arthritis Research and Therapy</i> , 2015 , 17, 208	5.7	20
84	Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. <i>BioMed Research International</i> , 2017 , 2017, 7915340	3	19
83	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	19
82	Restoration of t cell subsets of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells: An in vitro study. <i>Clinical Immunology</i> , 2016 , 163, 34-41	9	16
81	One year in review 2018: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 763-777	2.2	16
80	Polar extracts from the berry-like fruits of <i>Hypericum androsaemum</i> L. as a promising ingredient in skin care formulations. <i>Journal of Ethnopharmacology</i> , 2017 , 195, 255-265	5	15
79	Serum interleukin-17 in primary Sjögren's syndrome: association with disease duration and parotid gland swelling. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 129	2.2	15
78	Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2116-2124	7	14
77	Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?. <i>Frontiers in Immunology</i> , 2017 , 8, 554	8.4	14

76	Circulating Interferon-Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 440-5	4.7	14
75	Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis. <i>Autoimmunity Highlights</i> , 2010 , 1, 45-51	3.7	13
74	Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. <i>Hypertension</i> , 2016 , 68, 1504-1511	8.5	12
73	Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2016 , 20, 613-22	5.6	12
72	Ultrasound salivary gland involvement in Sjogren's syndrome vs. other connective tissue diseases: is it autoantibody and gland dependent?. <i>Clinical Rheumatology</i> , 2020 , 39, 1207-1215	3.9	11
71	Umbilical cord mesenchymal stem cells for the treatment of autoimmune diseases: beware of cell-to-cell contact. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e14	2.4	10
70	Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
69	The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. <i>Frontiers in Medicine</i> , 2018 , 5, 290	4.9	10
68	Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	9
67	Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 177	5.4	9
66	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. <i>PLoS ONE</i> , 2019 , 14, e0211142	3.7	8
65	Nutrition in RMDs: is it really food for thought? Focus on rheumatoid arthritis. <i>BMC Rheumatology</i> , 2020 , 4, 10	2.9	8
64	Patient-physician collaboration in rheumatology: a necessity. <i>RMD Open</i> , 2017 , 3, e000499	5.9	8
63	The dark side of Sjögren's syndrome: the possible pathogenic role of infections. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 505-511	5.3	8
62	Functional improvement of regulatory T cells from rheumatoid arthritis subjects induced by capsular polysaccharide glucuronoxylomannogalactan. <i>PLoS ONE</i> , 2014 , 9, e111163	3.7	7
61	Assessment of competences in rheumatology training: results of a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2020 , 6,	5.9	7
60	Remission of hyperglycemia in spontaneously diabetic NOD mice upon transplant of microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells (hUCMS). <i>Xenotransplantation</i> , 2019 , 26, e12476	2.8	7
59	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 192-198	2.2	7

58	Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?. <i>Frontiers in Immunology</i> , 2019 , 10, 817	8.4	6
57	The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e42	2.4	6
56	'Twitterland': a brave new world?. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1245-1246	2.4	6
55	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021 , 7,	5.9	6
54	The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 113-120	2.2	6
53	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
52	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014 , 5, 95-100	3.7	5
51	Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID?. <i>Viruses</i> , 2021 , 13,	6.2	5
50	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	5
49	Respiratory Manifestations in Systemic Lupus Erythematosus. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	5
48	The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience. <i>Frontiers in Medicine</i> , 2020 , 7, 608728	4.9	4
47	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 119-128	5.1	4
46	Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting. <i>Frontiers in Medicine</i> , 2020 , 7, 534	4.9	4
45	Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study. <i>RMD Open</i> , 2020 , 6,	5.9	4
44	Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations. <i>RMD Open</i> , 2020 , 6,	5.9	4
43	Anti -citrullinated peptide antibodies profiling in established rheumatoid arthritis. <i>Joint Bone Spine</i> , 2018 , 85, 441-445	2.9	4
42	Young people's perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force. <i>RMD Open</i> , 2021 , 7,	5.9	4
41	Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 1123-1124	2.2	4

40	Angiogenic T cells in primary Sjögren's syndrome: a double-edged sword?. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 36-41	2.2	4
39	One year in review 2021: pathogenesis of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 445-452	2.2	4
38	Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives. <i>RMD Open</i> , 2017 , 3, e000514	5.9	3
37	The challenge to interpret conflicting results and the need of a univocal definition for germinal centres in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e31	2.4	3
36	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 277-291	1.3	3
35	Laboratory Assessment of Patients with Suspected Rheumatic Musculoskeletal Diseases: Challenges and Pitfalls. <i>Current Rheumatology Reviews</i> , 2019 , 15, 27-43	1.6	3
34	Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021 , 7,	5.9	3
33	The Serological Status Affects the Prognostic Role of Salivary Gland Histology in Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2020 , 47, 1838	4.1	3
32	Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. <i>Joint Bone Spine</i> , 2021 , 88, 105198	2.9	3
31	FRI0193 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 2019 ,		3
30	Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 546-547	2.2	3
29	Novel insights on lymphoma and lymphomagenesis in primary Sjögren's Syndrome. <i>Panminerva Medica</i> , 2020 ,	2	2
28	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1116-1123	2.4	2
27	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 65-70	2.4	2
26	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 73-79	2.2	2
25	Novel Therapeutic Strategies in Primary Sjögren's Syndrome. <i>Israel Medical Association Journal</i> , 2017 , 19, 576-580	0.9	2
24	Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 210-214	2.2	2
23	Anticyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: Clinical or Pathogenic Significance?. <i>Journal of Rheumatology</i> , 2015 , 42, 1063-4	4.1	1

22	Mentoring for postdoctoral researchers in rheumatology: the Emerging EULAR Network (EMEUNET) post-doc mentoring programme. <i>RMD Open</i> , 2020 , 6,	5.9	1
21	Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
20	Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2021 , 8, 665028	4.9	1
19	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211022533	3.8	1
18	Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. <i>RMD Open</i> , 2021 , 7,	5.9	1
17	Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario?. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 133-139	2.2	1
16	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 938-946	2.2	1
15	Pathogenesis of rheumatoid arthritis: one year in review 2022.. <i>Clinical and Experimental Rheumatology</i> , 2022 , 40, 475-482	2.2	1
14	Adherence to the Mediterranean diet and the impact on clinical features in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 190-196	2.2	1
13	Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a 'mix-and-match' approach?. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	0
12	Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. <i>Frontiers in Medicine</i> , 2021 , 8, 779975	4.9	0
11	Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e54	2.4	0
10	Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1200-1204	5.3	0
9	A Platelet's Guide to Synovitis. <i>Israel Medical Association Journal</i> , 2019 , 21, 454-459	0.9	0
8	A3.1 Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A42.1-A42	2.4	
7	A3.8 Association between clinical, histopathological and molecular features in primary Sjögren's Syndrome: a retrospective study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A45.1-A45	2.4	
6	A3.4 CD3+CD4+CD8+ Double Negative Th17 Cells: New Insights in the Pathogenesis of Primary Sjögren's Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A14.2-A15	2.4	
5	Comment on: Equal rights in autoimmunity: is Sjögren's syndrome ever 'secondary'?. <i>Rheumatology</i> , 2021 , 60, e32-e33	3.9	

- | | | |
|---|--|-----|
| 4 | Different clinical presentations of primary Sjögren's syndrome: Not only a matter of age. Comment on: "Elderly-onset primary Sjögren's syndrome focused on clinical and salivary gland ultrasonographic features by Lee et al. <i>Joint Bone Spine</i> . 2021;88:105132". <i>Joint Bone Spine</i> , 2021 , 88, 105191 | 2.9 |
| 3 | Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 445 | 2.2 |
| 2 | Characterisation of articular manifestations in primary Sjögren's syndrome: clinical and imaging features. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 166-173 | 2.2 |
| 1 | Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 189-194 | 2.2 |